UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2005

or

¨ Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from                      to                      .

Commission File No. 000-21001

NMT MEDICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	95-4090463
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
27 Wormwood Street, Boston, Massachusetts	02210-1625
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (617) 737-0930

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No ¨

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No x

As of November 1, 2005, there were 12,421,878 shares of Common Stock, $.001 par value per share, outstanding.

INDEX

	Page Number
Part I. Financial Information
Item 1. Financial Statements (unaudited)
Consolidated Balance Sheets at September 30, 2005 and December 31, 2004	3
Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2005 and 2004	4
Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2005 and 2004	5
Notes to Consolidated Financial Statements	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3. Quantitative and Qualitative Disclosures About Market Risk	22
Item 4. Controls and Procedures	23
Part II. Other Information
Item 1. Legal Proceedings	23
Item 6. Exhibits	25
Signatures	26

2

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

NMT Medical, Inc. and Subsidiaries

Consolidated Balance Sheets

(unaudited)

	At September 30, 2005			At December 31, 2004
Assets
Current assets:
Cash and cash equivalents	$	11,430,299		$	9,338,208
Marketable securities		21,988,400			24,919,460
Restricted cash		—			1,122,200
Accounts receivable, net of reserves of $369,984 in 2005 and $378,403 in 2004		2,313,613			1,776,605
Inventories		1,889,621			2,523,062
Prepaid expenses and other current assets		2,775,892			2,864,600
Total current assets		40,397,825			42,544,135
Property and equipment, net		692,738			790,361
Other assets		7,293			29,263
	$	41,097,856		$	43,363,759
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	2,253,764		$	1,682,272
Accrued expenses		5,594,692			4,309,586
Discontinued operations liabilities		—			500,000
Total current liabilities		7,848,456			6,491,858
Commitments and contingencies (Note 11)
Stockholders’ equity :
Preferred stock, $.001 par value     Authorized—3,000,000 shares     Issued and outstanding—none		—			—
Common stock, $.001 par value     Authorized—30,000,000 shares     Issued—12,458,252 shares in 2005 and         12,176,183 in 2004		12,459			12,176
Additional paid-in capital		47,536,662			46,093,075
Less: treasury stock - 40,000 shares at cost		(119,600	)		(119,600	)
Accumulated other comprehensive loss		(92,685	)		(152,596	)
Accumulated deficit		(14,087,436	)		(8,961,154	)
Total stockholders’ equity		33,249,400			36,871,901
	$	41,097,856		$	43,363,759

See accompanying notes.

3

NMT Medical, Inc. and Subsidiaries

Consolidated Statements of Operations

(unaudited)

	For The Three Months Ended September 30,						For The Nine Months Ended September 30,
	2005			2004			2005			2004
Revenues:
Product sales	$	4,925,617		$	3,947,196		$	14,214,768		$	13,484,183
Net royalty income		1,115,776			1,078,325			3,448,301			2,957,014
Total revenues		6,041,393			5,025,521			17,663,069			16,441,197
Expenses:
Cost of product sales		1,391,468			1,030,586			4,049,143			3,428,154
Research and development		4,325,914			2,043,265			11,026,922			6,134,648
General and administrative		1,121,882			1,183,163			3,766,907			3,697,210
Selling and marketing		1,483,065			1,318,082			4,528,401			4,328,619
Total costs and expenses		8,322,329			5,575,096			23,371,373			17,588,631
Loss from operations		(2,280,936	)		(549,575	)		(5,708,304	)		(1,147,434	)
Other Income (Expense):
Interest income, net		229,443			134,025			592,239			388,692
Foreign currency transaction (loss) gain		(8,439	)		5,606			(100,904	)		(7,390	)
Total other income, net		221,004			139,631			491,335			381,302
Loss from continuing operations		(2,059,932	)		(409,944	)		(5,216,969	)		(766,132	)
Income from discontinued operations		—			—			90,687			—
Net loss	$	(2,059,932	)	$	(409,944	)	$	(5,126,282	)	$	(766,132	)
Net (loss) income per common share:
Continuing operations	$	(0.17	)	$	(0.03	)	$	(0.43	)	$	(0.06	)
Discontinued operations		—			—			0.01			—
Net loss	$	(0.17	)	$	(0.03	)	$	(0.42	)	$	(0.06	)
Weighted average common shares outstanding:
Basic and Diluted		12,373,146			12,070,800			12,274,488			12,002,783

See accompanying notes.

4

NMT Medical, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(unaudited)

	For the Nine Months Ended September 30,
	2005			2004
Cash flows from operating activities:
Net loss	$	(5,126,282	)	$	(766,132	)
Income from discontinued operations		(90,687	)		—
Loss from continuing operations		(5,216,969	)		(766,132	)
Adjustments to reconcile net loss to net cash used in operating activities —
Depreciation and amortization		668,281			584,352
Stock-based employee compensation		257,188			(18,867	)
Changes in assets and liabilities —
Accounts receivable		(537,008	)		670,608
Inventories		633,441			(532,567	)
Prepaid expenses and other current assets		28,662			(738,910	)
Accounts payable		571,492			531,666
Accrued expenses		1,260,106			(755,603	)
Net cash used in operating activities		(2,334,807	)		(1,025,453	)
Net cash used in discontinued operations		(324,267	)		—
Cash flows from investing activities:
Purchases of property and equipment		(135,352	)		(334,522	)
Purchases of marketable securities		(12,792,365	)		(22,624,197	)
Proceeds from maturities of marketable securities		15,370,000			8,000,000
Decrease in restricted cash		1,122,200			—
Net cash provided by (used in) investing activities		3,564,483			(14,958,719	)
Cash flows from financing activities:
Proceeds from exercise of common stock options and warrants		964,596			308,759
Proceeds from issuance of common stock pursuant to employee stock purchase plan		222,086			206,685
Net cash provided by financing activities		1,186,682			515,444
Net increase (decrease) in cash and cash equivalents		2,092,091			(15,468,728	)
Cash and cash equivalents, beginning of period		9,338,208			28,724,767
Cash and cash equivalents, end of period	$	11,430,299		$	13,256,039
Supplemental disclosure of cash flow information:
Cash paid during the period for
Interest	$	—		$	951
Income taxes	$	—		$	488,750

See accompanying notes.

5

NMT Medical, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

1. Operations

We are an advanced medical technology company that designs, develops and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other brain attacks through minimally invasive, catheter-based procedures. We are investigating the potential connection between a common cardiac defect called a patent foramen ovale (“PFO”) and brain attacks such as migraine headaches, stroke and transient ischemic attacks (“TIA”). A PFO can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack. We are a leader in designing and developing implants to seal the PFO defect in a minimally invasive, catheter-based procedure performed by an interventional cardiologist.

2. Interim Financial Statements

The accompanying consolidated financial statements at September 30, 2005 and for the three and nine-month periods ended September 30, 2005 and 2004 are unaudited and include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In our opinion, these unaudited consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2004, and include all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the results for such interim periods. These financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2004. The results of operations for the three and nine-month periods ended September 30, 2005 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2005.

Certain footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures in these financial statements are adequate to make the information presented not misleading.

3. Stock-Based Compensation

We account for stock-based compensation using the intrinsic value method prescribed in Accounting Principles Board Opinion (“APB”) No. 25, “Accounting for Stock Issued to Employees”, and related interpretations. Under APB No. 25, no compensation expense is recognized when the option price is equal to the market price of the underlying stock on the date of grant. Under an alternative method of accounting, Statement of Financial Accounting Standards (“SFAS”) No. 123, “Accounting for Stock-Based Compensation”, options are valued at the grant date using an option pricing model and compensation expense is recognized ratably over the vesting period. The following table illustrates the pro forma effect on net loss and net loss per share if we had applied the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation:

	For The Three Months Ended September 30,						For The Nine Months Ended September 30,
	2005			2004			2005			2004
Net loss as reported	$	(2,059,932	)	$	(409,944	)	$	(5,126,282	)	$	(766,132	)
Add: Stock-based employee compensation included in net loss as reported		—			17,169			257,188			(18,867	)
Less: Total stock-based employee compensation expense determined under fair value-based methods for all awards		(431,078	)		(284,700	)		(979,680	)		(921,846	)
Pro forma net loss	$	(2,491,010	)	$	(677,475	)	$	(5,848,774	)	$	(1,706,845	)
Basic and Diluted net loss per common share:
As reported	$	(0.17	)	$	(0.03	)	$	(0.42	)	$	(0.06	)
Pro forma	$	(0.20	)	$	(0.06	)	$	(0.48	)	$	(0.14	)

6

NMT Medical, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

3. Stock-Based Compensation (continued)

Our stock option grants generally vest over several years and we intend to grant varying levels of stock options in future periods. Therefore, the pro forma effects of applying SFAS No. 123 for the three and nine-month periods ended September 30, 2005 and 2004 are not necessarily indicative of the effects expected in future periods. See Note 10 for a discussion of certain recent accounting developments relating to stock-based compensation.

4. Cash, Cash Equivalents and Marketable Securities

We consider investments with maturities of 90 days or less from the date of purchase to be cash equivalents and investments with original maturity dates greater than 90 days to be marketable securities.

Available-for-sale marketable securities at September 30, 2005 consisted of approximately $22.0 million of debt instruments with maturities ranging from October 2005 to November 2006. Approximately $93,000 of accumulated unrealized losses were recorded at September 30, 2005 as a component of accumulated other comprehensive loss. Accrued interest receivable of approximately $210,000 and $357,000 were included in prepaid expenses and other current assets in the accompanying consolidated balance sheets at September 30, 2005 and December 31, 2004, respectively.

On September 16, 2005, a bank guarantee was released in connection with our settlement of a French tax claim (see Note 7). As a result, approximately $1.1 million of cash used to collateralize the bank guarantee was no longer restricted at September 30, 2005.

5. Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market and consisted of the following:

	At September 30, 2005		At December 31, 2004
Raw materials and work-in-process	$	777,006	$	1,165,310
Finished goods		1,112,615		1,357,752
	$	1,889,621	$	2,523,062

Finished goods and work-in-process consisted of materials, labor and manufacturing overhead.

6. Net Royalty Income

Royalties earned from C.R. Bard, Inc. (“Bard”) and Boston Scientific Corporation (“BSC”) are reported in the accompanying consolidated statements of operations net of related royalty obligations due to third parties.

7. Discontinued Operations

On July 6, 2005, we settled a French tax claim related to our former neurosciences business unit, which was sold in 2002 to Integra LifeSciences Holding Corporation (“Integra”). Pursuant to an indemnification agreement, we paid $324,267 to Integra, which amount was net of a previous deposit payment of approximately $60,000. In connection with this settlement, we recorded income from discontinued operations of $90,687 in the second quarter of 2005.

8. Net Loss per Common and Common Equivalent Share

Basic and diluted net loss per common share are presented in conformity with SFAS No. 128, “Earnings per Share”, for all periods presented. In accordance with SFAS No. 128, basic and diluted net loss per common share were determined by dividing net loss by the weighted average common shares outstanding during the periods presented. Options and warrants to purchase a total of 1,740,201 and 1,894,968 common shares have been excluded from the computation of diluted weighted average shares outstanding for the three and nine-month periods ended September 30, 2005 and 2004, respectively, because they were not dilutive.

7

NMT Medical, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

9. Comprehensive (Loss) Income

We apply the provisions of SFAS No. 130, “Reporting Comprehensive Income”, which establishes standards for reporting and disclosing comprehensive (loss) income and its components in the consolidated financial statements. Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

	For The Three Months Ended September 30,						For The Nine Months Ended September 30,
	2005			2004			2005			2004
Net loss	$	(2,059,932	)	$	(409,944	)	$	(5,126,282	)	$	(766,132	)
Unrealized gain (loss) on marketable securities		30,065			64,646			59,911			(120,634	)
Net comprehensive loss	$	(2,029,867	)	$	(345,298	)	$	(5,066,371	)	$	(886,766	)

The accumulated other comprehensive loss in the accompanying consolidated balance sheets consists entirely of unrealized losses on marketable securities.

10. Recent Accounting Pronouncements

On December 16, 2004, the Financial Accounting Standards Board (FASB) issued FASB Statement No. 123 (revised 2004), “Share-Based Payment”, which is a revision of FASB Statement No. 123, “Accounting for Stock-Based Compensation”. Statement 123(R) supersedes APB Opinion No. 25, “Accounting for Stock Issued to Employees”, and amends FASB Statement No. 95, “Statement of Cash Flows”. Generally, the approach in Statement 123(R) is similar to the approach described in Statement 123. However, Statement 123(R) requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Following January 1, 2006, pro forma disclosure is no longer an alternative.

Statement 123(R) must be adopted no later than January 1, 2006. Early adoption will be permitted in periods in which financial statements have not yet been issued. We expect to adopt Statement 123(R) on January 1, 2006.

Statement 123(R) permits public companies to adopt its requirements using one of two methods:

• A “modified prospective” method in which compensation cost is recognized beginning with the effective date (a) based on the requirements of Statement 123(R) for all share-based payments granted after the effective date and (b) based on the requirements of Statement 123 for all awards granted to employees prior to the effective date of Statement 123(R) that remain unvested on the effective date.

• A “modified retrospective” method which includes the requirements of the modified prospective method described above, but also permits entities to restate based on the amounts previously recognized under Statement 123 for purposes of pro forma disclosures based upon either (a) all prior periods presented or (b) prior interim periods of the year of adoption.

We have not yet determined which alternative method of applying Statement 123(R) will be adopted.

As permitted by Statement 123, we currently account for share-based payments to employees using Opinion 25’s intrinsic value method and, as such, generally recognize no compensation cost for employee stock options. Accordingly, the adoption of Statement 123(R)’s fair value method will have a significant impact on our result of operations, although it will have no impact on our overall financial position. The impact of adoption of Statement 123(R) cannot be predicted at this time because it will depend, in part, on levels of share-based payments granted in the future. However, had we adopted Statement 123(R) in prior periods, the impact of that standard would have approximated the impact of Statement 123 as described in the disclosure of pro forma net loss and net loss per share in Note 3 to our consolidated financial statements. Statement 123(R) also requires the benefits of tax deductions in excess of recognized compensation cost to be reported as a financing cash flow, rather than as an operating cash flow as required under current literature. This requirement will reduce net operating cash flows and increase net financing cash flows in periods after adoption.

8

NMT Medical, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

11. Commitments and Contingencies

(a) Litigation

In September 2004, we and Children’s Medical Center Corporation (“CMCC”) filed a civil complaint in the U.S. District Court for the District of Minnesota for infringement of a patent owned by CMCC and licensed exclusively to us. The complaint alleges that Cardia of Burnsville, Minnesota is manufacturing, selling and/or offering to sell a medical device in the United States that infringes CMCC’s U.S. patent relating to a device and method for repairing septal defects. We sought an injunction from the court to prevent further infringement by Cardia, as well as monetary damages. The court has entered a pre-trial order stating that the case is to be ready for trial in the spring of 2006.

On March 22, 1999, we filed a patent infringement suit in the United States District Court for the District of Massachusetts (the “Court”) against AGA Medical Corporation (“AGA”) alleging that AGA was infringing United States Patent No. 5,108,420 (the “‘420 patent”), relating to aperture occlusion devices, to which we have an exclusive license. We sought an injunction from the Court to prevent further infringement by AGA, as well as monetary damages. On April 12, 1999, AGA served its answer and counterclaims denying liability and alleging that we had engaged in false or misleading advertising and in unfair or deceptive business practices. AGA’s counterclaims sought an injunction and an unspecified amount of damages. On May 3, 1999, we answered AGA’s counterclaims denying liability. On April 25, 2001, the Court granted our motion to stay all proceedings in this matter pending reexamination of the ‘420 patent by the United States Patent and Trademark Office and, on December 2, 2003, the Court dismissed our claim and AGA’s counterclaim without prejudice to our ability to refile suit after the conclusion of the reexamination proceedings. Although a Patent Office examiner initially rejected the claims of the ‘420 patent, on August 19, 2004, the Board of Patent Appeals and Interferences reversed the examiners rejection of the claims of the ‘420 patent and returned the reexamination for action consistent with its decision. On January 26, 2005, the Patent Office mailed a Notice of Intent to Issue a Reexamination Certificate. This reexamination certificate was issued on June 7, 2005. On October 13, 2004, AGA initiated a declaratory action in the United States District Court for the District of Minnesota seeking a declaration that the ‘420 patent is invalid, unenforceable, and not infringed. On December 7, 2004, we revived our original Massachusetts action by filing a complaint alleging that AGA is infringing the ‘420 patent. On September 1, 2005, AGA’s declaratory judgment action in the United States District Court for the District of Minnesota was transferred to the District of Massachusetts.

On July 6, 2005, we settled a French tax claim related to our former neurosciences business unit (see Note 7).

(b) Clinical Trials

MIST III

In October 2005, we received approval from the regulatory authorities in the United Kingdom to begin enrollment in MIST III (Migraine Intervention with STARFlex^® Technology). In MIST III, control patients from the original MIST study, those who did not receive the STARFlex^® implant, have the option to receive an implant after they have been unblinded as part of the MIST study. Patients who choose to receive an implant will be followed for six months. These patients will then be followed for an additional 18 months and will become their own control. In addition, migraine patients with a PFO who did receive a STARFlex^® implant in MIST will be followed for an additional 18 months. We currently estimate the cost of MIST III to be approximately $1.0 million.

MIST II

In September 2005, we received conditional approval from the U.S. Food and Drug Administration (“FDA”) of an Investigational Device Exemption (“IDE”) to initiate enrollment in our pivotal PFO/migraine clinical study, named MIST II. MIST II is a prospective, randomized, multi-center, controlled study. The double-blinded trial is designed to randomize approximately 600 migraine patients with a PFO to either PFO closure with our STARFlex^® technology or a control arm. The study will incorporate our newest, most technologically advanced delivery system. Twenty U.S. research centers have committed to participate in MIST II, for which enrollment is currently expected to begin in early 2006, with patient follow-up over a one year period. We currently project the costs of this clinical study to be in the range of $16 - $20 million through 2008, of which 2005 costs are estimated to approximate $500,000.

9

NMT Medical, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

11. Commitments and Contingencies (continued)

BEST

In June 2005, we received approval in the United Kingdom for our BioSTAR^™ Evaluation STudy (BEST), a multi-center study designed to evaluate our new BioSTAR^™ PFO closure technology, the first in-human use of a bioabsorbable collagen matrix incorporated on our STARFlex^® platform. Patient enrollment was initiated in July 2005 and is expected to be completed by the end of the fourth quarter 2005. The goal of this BEST study is to secure European commercial approval for our novel BioSTAR™ technology through the Conformité Europeene (“CE Mark”) process. We currently estimate total costs of this study, including third party contracts and agreements with clinical sites and other service providers, to be in the range of $1.5 – $2.0 million, of which approximately $1.4 – $1.6 million is currently anticipated to be incurred in 2005. Of this total, approximately $600,000 was incurred during the nine months ended September 30, 2005.

MIST

In November 2004, we received approval in the United Kingdom for our Migraine Intervention with STARFlex^® Technology (MIST) study, the first prospective, randomized, double-blinded study using our proprietary STARFlex^® septal repair technology to evaluate a possible connection between transcatheter PFO closure and migraine headaches. Study enrollment of 147 migraine headache patients with a PFO was completed in early July 2005. These patients will be subject to follow-up evaluation over a six-month period. We currently estimate total costs of this study, including third party contracts and agreements with clinical sites and other service providers, to be approximately $4.0 million through early 2006. Of this total, approximately $900,000 was incurred during 2004 and we currently estimate 2005 costs to be approximately $2.9 million, of which approximately $2.5 million was incurred during the nine months ended September 30, 2005.

CLOSURE I

In June 2003, the FDA approved our IDE clinical trial comparing our fourth generation STARFlex^® cardiac septal repair implant with medical therapy in preventing recurrent stroke and transient ischemic attack. The trial is expected to enroll approximately 1,600 patients at approximately 100 leading stroke and interventional cardiology centers in the United States, with half receiving a STARFlex^® implant and the other half receiving drug therapy. Patient enrollment, which totaled approximately 380 at September 30, 2005, has progressed much slower than anticipated. We are continuing to work with our consultants, regulatory bodies and investigators to help complete enrollment by the end of 2006, but full enrollment may take longer. In connection with CLOSURE I, we have entered into various contractual obligations with third party service providers and the participating clinical sites. Including the internal costs of our clinical department and the manufacturing costs of our STARFlex^® products to be implanted, we currently estimate total CLOSURE I costs to be approximately $24 million through the completion of the trial and submission to the FDA. Of this total, approximately $6.2 million of costs were incurred through 2004. We currently estimate 2005 costs to be approximately $3.5 million, of which approximately $2.4 million was incurred in the nine months ended September 30, 2005. The timing and amount of these obligations are dependent on various factors, including the timing of patient enrollment and patient monitoring. Under certain agreements with third party service providers, we have the right to terminate, in which case the remaining obligations under such agreements would be limited to costs incurred as of that date.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of the financial condition and results of operations of the Company should be read in conjunction with the Consolidated Financial Statements and Notes thereto included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2004. This Quarterly Report on Form 10-Q contains forward-looking statements based on our current expectations, assumptions, estimates and projections about the Company and our industry. These forward-looking statements are usually accompanied by words such as “believes”, “anticipates”, “plans”, “expects” and similar expressions. Forward-looking statements involve risks and uncertainties, and our actual results may differ materially from the results anticipated in these forward-looking statements as a result of certain factors, as more fully described in this section under the caption “Certain Factors That May Affect Future Results”.

CRITICAL ACCOUNTING POLICIES

Certain of our accounting policies are particularly important to the portrayal and understanding of our financial position and results of operations and require the application of significant judgment by our management. As a result, these policies are

10

subject to an inherent degree of uncertainty. In applying these policies, we use our judgment in making certain assumptions and estimates. Our critical accounting policies, which consist of revenue recognition, accounts receivable reserves, inventories, legal contingencies and expenses associated with clinical trials, are described in our Annual Report on Form 10-K for the year ended December 31, 2004. There have been no material changes to our critical accounting policies as of September 30, 2005.

RESULTS OF OPERATIONS

THREE MONTHS ENDED SEPTEMBER 30, 2005 COMPARED WITH THREE MONTHS ENDED SEPTEMBER 30, 2004

The following table presents consolidated statements of operations information as a reference for management’s discussion and analysis which follows thereafter. This table presents dollar and percentage changes for each listed line item for the three months ended September 30, 2005 compared to the three months ended September 30, 2004, as well as consolidated statements of operations information as a percentage of total revenues (except for cost of product sales, which is stated as a percentage of total product sales) for such periods.

	Three Months Ended September 30,										Increase (Decrease) 2004 to 2005			% Change 2004 to 2005
	2005			%		2004			%
	(In thousands, except percentages)
Revenues:
Product sales	$	4,926		81.5	%	$	3,947		78.5	%	$	979		24.8	%
Net royalty income		1,115		18.5	%		1,078		21.5	%		37		3.4	%
Total revenues		6,041		100.0	%		5,025		100.0	%		1,016		20.2	%
Costs and expenses:
Cost of product sales		1,391		28.2	%		1,031		26.1	%		360		34.9	%
Research and development		4,326		71.6	%		2,043		40.7	%		2,283		111.7	%
General and administrative		1,122		18.6	%		1,183		23.5	%		(61	)	(5.2	)%
Selling and marketing		1,483		24.5	%		1,318		26.2	%		165		12.5	%
Total costs and expenses		8,322		137.8	%		5,575		110.9	%		2,747		49.3	%
Loss from operations		(2,281	)	(37.8	)%		(550	)	(10.9	)%		(1,731	)	314.7	%
Other Income (Expense):
Interest income, net		229		3.8	%		134		2.7	%		95		70.9	%
Foreign currency transaction (loss) income		(8	)	(0.1	)%		6		0.1	%		(14	)	(233.3	)%
Total other income, net		221		3.7	%		140		2.8	%		81		57.9	%
Net loss	$	(2,060	)	(34.1	)%	$	(410	)	(8.2	)%	$	(1,650	)	402.4	%

11

Revenues. Total revenues for the three months ended September 30, 2005 and 2004 were as follows:

	For The Three Months Ended September 30,				Increase (Decrease) 2004 to 2005			% Change 2004 to 2005
	2005		2004
	(In thousands, except percentages)
Product sales:
CardioSEAL® and STARFlex®:
North America	$	4,211	$	3,150	$	1,061		33.7	%
Europe		715		797		(82	)	(10.3	)%
Total product sales		4,926		3,947		979		24.8	%
Net royalty income:
Bard		1,080		1,026		54		5.3	%
BSC		35		52		(17	)	(32.7	)%
Total net royalty income		1,115		1,078		37		3.4	%
Total revenues	$	6,041	$	5,025	$	1,016		20.2	%

The increase in CardioSEAL^® and STARFlex^® product sales was attributable to United States and Canadian operations. New customers in both of these two countries were significant contributors to increased product sales during the three months ended September 30, 2005. We believe that this was attributable to a combination of increased market awareness of PFO closure and targeted marketing efforts. A higher proportion of distributor versus direct European unit sales and a slight strengthening of the U.S. dollar for the three months ended September 30, 2005 compared to 2004 accounted for the approximate 10% reduction in European product sales. European sales represented approximately 14.5% and 20.2% of total CardioSEAL^® and STARFlex^® product sales for the three months ended September 30, 2005 and 2004, respectively.

Management currently anticipates fourth quarter product sales to be slightly greater than sales levels of the most recent two quarters, resulting in an approximate 10% - 12% increase in CardioSEAL^® and STARFlex^® product sales for the full year 2005 compared to 2004. We currently expect this increase to be substantially attributable to United States and Canadian sales, related to new customer accounts and increased PFO closure market activity. European product sales are expected to approximate 18% - 20% of total product sales for the full year 2005, down from approximately 20.8% for 2004. Additionally, incremental weakening or strengthening of the U.S. dollar will have a favorable or unfavorable impact, respectively, on European product sales. Pending the MIST study data results expected early in 2006 and the potential awarding of the CE Mark for BioSTAR™, we currently believe that our European product sales will increase compared to current year levels.

Slightly higher net royalty income was primarily attributable to increased sales by Bard of its Recovery^™ Filter (“RNF”) product. The royalty income from Bard was recorded net of approximately $364,000 of royalties payable to the original inventor of the Simon Nitinol Filter (“SNF”) and RNF products. Although we currently anticipate that net royalties earned from Bard will increase in the range of 10% - 12% for the full year 2005 compared to 2004 levels, that result is largely dependent upon continued market acceptance and penetration of Bard’s RNF product. As expected, net royalty income from BSC related to the 1994 exclusive license of our stent technology decreased from 2004 to 2005. We currently anticipate that future royalties earned from BSC will remain flat or decline compared to 2004 levels.

Cost of Product Sales. The increase in cost of product sales, as a percentage of total product sales, was primarily due to 2005 production volumes below normalized plant capacity levels. As a result, a portion of our 2005 fixed manufacturing overhead costs were not absorbed as part of the standard inventory unit costs, but instead were charged to cost of product sales in the period incurred. Also contributing slightly to the increase was a lower average selling price in 2005 resulting from a higher proportion of distributor versus direct European sales, partially offset by a higher proportion of United States and Canadian sales versus European sales. For the full year 2005, we currently expect cost of product sales as a percentage of total product sales to be approximately 29% - 30%, compared to approximately 26% for fiscal 2004, primarily as a result of production volumes below normalized plant capacity levels and a lower weighted average unit selling price. Included in cost of product sales were royalty expenses of approximately $482,000 and $377,000 for the three months ended September 30, 2005 and 2004, respectively.

12

Research and Development. The approximate 112% increase in research and development expense was primarily related to (i) increased legal fees of approximately $700,000 associated with patent infringement claims against Cardia and AGA and ongoing patent research; (ii) approximately $425,000 of costs related to our BEST clinical study, for which patient enrollment was commenced in July 2005 and is expected to be completed by the end of the fourth quarter of 2005; (iii) increased costs of approximately $400,000 related to our MIST UK clinical study, for which patient enrollment was completed in early July 2005; (iv) $300,000 of technology license and development fees related to BioSTAR™, our most advanced implant technology; and (v) increased headcount and related personnel costs of approximately $200,000. Combined costs of our CLOSURE I, MIST UK and BEST clinical studies totaled approximately $1.9 million for the three months ended September 30, 2005 compared to approximately $1.0 million for the three months ended September 30, 2004.

We currently expect 2005 research and development expense to increase to approximately $16.5 million compared to approximately $9.0 million in 2004, an approximate 83% increase, primarily attributable to (i) the ongoing MIST study; (ii) completion of enrollment in the BEST clinical study; (iii) initial costs related to the anticipated early 2006 commencement of the MIST IDE clinical trial in the U.S., for which we received conditional FDA approval in September 2005; (iv) prosecution of existing patent infringement claims; and (v) investments in our future PFO closure technologies. We currently expect total costs for the current MIST study to approximate $4.0 million through completion in early 2006, of which approximately $900,000 was incurred during 2004 and we currently estimate 2005 costs to be approximately $2.9 million. We continue to estimate total CLOSURE I costs of approximately $24 million through the end of the clinical trial and submission to the FDA. Of this total, approximately $6.0 million of research and development expense was incurred through the end of 2004, and we currently estimate 2005 costs to be approximately $3.5 million, largely dependent upon the rate of patient enrollment. We currently estimate total costs for our BEST study to be in the range of $1.5 - $2.0 million, of which approximately $1.4 - $1.6 million is currently anticipated to be incurred in 2005. Of this total, approximately $600,000 was incurred during the nine months ended September 30, 2005. We currently expect research and development expense as a percentage of total revenues to be approximately 70% for fiscal year 2005 compared to 42% in 2004.

General and Administrative. The slight decrease in general and administrative expense was primarily attributable to reduced corporate legal fees of approximately $102,000 and reduced insurance costs of approximately $20,000, partially offset by increased professional fees of approximately $60,000 principally related to increased corporate governance requirements of the Sarbanes-Oxley Act (“SOX”). As of June 30, 2005, we met the Securities and Exchange Commission (“SEC”) definition of an accelerated filer. As a result, our independent registered public accountants will be required to provide their attestation of our certification of internal controls over financial reporting under Section 404 of SOX commencing for fiscal year 2005. General and administrative expense is currently expected to increase by approximately 5% in fiscal year 2005 compared to 2004, primarily related to (i) the aforementioned requirements of SOX and (ii) increased stock-based compensation related to our 2001 stock option re-pricing, for which compensation expense was finalized in the second quarter of 2005 coincident with the end of the four year vesting period of the underlying options, partially offset by reduced corporate legal fees. We currently expect general and administrative expense as a percentage of total revenues to decrease to approximately 22% for fiscal 2005 compared to approximately 24% in 2004.

Selling and Marketing. The increase in selling and marketing expense was primarily attributable to (i) increased sales incentive compensation of approximately $168,000 due to higher North American product sales and (ii) increased headcount and related costs of approximately $138,000, primarily related to UK expansion, partially offset by (i) the non-recurrence of approximately $47,000 of 2004 costs associated with our collaboration with the National Stroke Association to promote market awareness of the potential relationship between PFO and recurrent stroke and (ii) reduced marketing program events of approximately $76,000. We currently expect total selling and marketing expense to increase by approximately 15% for fiscal 2005 compared to 2004, primarily related to higher sales-based commissions and planned sales and marketing efforts during the second half of 2005 in anticipation of increased future sales in Europe. We currently expect selling and marketing expense as a percentage of total revenues to be approximately 26% for fiscal year 2005 and 2004.

Interest Income. The increase in interest income was primarily attributable to the trend of increasing short-term interest rates, partially offset by an approximate $1.0 million reduction in average interest-bearing assets. We currently expect full year 2005 interest income to increase approximately 45% compared to 2004 due to the effect of incrementally higher interest rate yields, partially offset by a projected reduction in cash equivalent and marketable securities balances of approximately $5.0 million during the year ending December 31, 2005 to fund our MIST, MIST II, MIST III, CLOSURE I and BEST studies and other research and development initiatives.

Income Tax Provision. We recorded no income tax provision for each of the three-month periods ended September 30, 2005 and 2004 on the basis that our planned investments in MIST, MIST II, MIST III, CLOSURE I and BEST were expected to result in net operating losses for each of these fiscal years. Accordingly, we currently expect a nominal income tax provision, if any, for the year ending December 31, 2005.

13

NINE MONTHS ENDED SEPTEMBER 30, 2005 COMPARED WITH NINE MONTHS ENDED SEPTEMBER 30, 2004

The following table presents consolidated statements of operations information as a reference for management’s discussion and analysis which follows thereafter. This table presents dollar and percentage changes for each listed line item for the nine months ended September 30, 2005 compared to the nine months ended September 30, 2004, as well as consolidated statements of operations information as a percentage of total revenues (except for cost of product sales, which is stated as a percentage of total product sales) for such periods.

	Nine Months Ended September 30,										Increase (Decrease) 2004 to 2005			% Change 2004 to 2005
	2005			%		2004			%
	(In thousands, except percentages)
Revenues:
Product sales	$	14,215		80.5	%	$	13,484		82.0	%	$	731		5.4	%
Net royalty income		3,448		19.5	%		2,957		18.0	%		491		16.6	%
Total revenues		17,663		100.0	%		16,441		100.0	%		1,222		7.4	%
Costs and expenses:
Cost of product sales		4,049		28.5	%		3,429		25.4	%		620		18.1	%
Research and development		11,027		62.4	%		6,134		37.3	%		4,893		79.8	%
General and administrative		3,767		21.3	%		3,697		22.5	%		70		1.9	%
Selling and marketing		4,528		25.6	%		4,329		26.3	%		199		4.6	%
Total costs and expenses		23,371		132.3	%		17,589		107.0	%		5,782		32.9	%
Loss from operations		(5,708	)	(32.3	)%		(1,148	)	(7.0	)%		(4,560	)	397.2	%
Other Income (Expense):
Interest income, net		592		3.4	%		389		2.4	%		203		52.2	%
Foreign currency transaction loss		(101	)	(0.6	)%		(7	)	(0.0	)%		(94	)	1342.9	%
Total other income, net		491		2.8	%		382		2.3	%		109		28.5	%
Loss from continuing operations		(5,217	)	(29.5	)%		(766	)	(4.7	)%		(4,451	)	581.1	%
Income from discontinued operations		91		0.5	%		—		—			91		—
Net loss	$	(5,126	)	(29.0	)%	$	(766	)	(4.7	)%	$	(4,360	)	569.2	%

14

Revenues. Total revenues for the nine months ended September 30, 2005 and 2004 were as follows:

	For The Nine Months Ended September 30,				Increase (Decrease) 2004 to 2005			% Change 2004 to 2005
	2005		2004
	(In thousands, except percentages)
Product sales:
CardioSEAL® and STARFlex®:
North America	$	11,660	$	10,774	$	886		8.2	%
Europe		2,555		2,555		—		0.0	%
		14,215		13,329		886		6.6	%
Other		—		155		(155	)	(100.0	)%
Total product sales		14,215		13,484		731		5.4	%
Net royalty income:
Bard		3,330		2,732		598		21.9	%
BSC		118		225		(107	)	(47.6	)%
Total net royalty income		3,448		2,957		491		16.6	%
Total revenues	$	17,663	$	16,441	$	1,222		7.4	%

The increase in CardioSEAL^® and STARFlex^® product sales for the nine months ended September 30, 2005 compared to the nine months ended September 30, 2004 was attributable to United States and Canadian operations. Primarily as a result of new customers in these two countries, we achieved year-over-year sales increases during the second and third quarters of 2005, the first such increases since 2003, which more than offset the year-over-year decrease in the first quarter of 2005 compared to 2004. European product sales for the nine months ended September 30, 2005 were flat compared to the nine months ended September 30, 2004, primarily due to a higher proportion of distributor versus direct unit sales offset by the effect of the weaker U.S. dollar relative to the Euro currency. European sales represented approximately 18.0% and 19.2% of total CardioSEAL^® and STARFlex^® product sales for the nine months ended September 30, 2005 and 2004, respectively.

Increased net royalty income was directly attributable to higher sales by Bard of its RNF product, for which Bard received FDA regulatory approval for commercial sale and use as of December 31, 2002, partially offset by a continuing downward trend of BSC royalty income.

Cost of Product Sales. The increase in cost of product sales, as a percentage of total product sales, was primarily due to 2005 production volumes below normalized plant capacity levels. As a result, a portion of our 2005 fixed manufacturing overhead costs were not absorbed as part of the standard inventory unit costs, but instead were charged to cost of product sales in the period incurred. The increase was also impacted by a 5.6% reduction in the weighted average European selling price in 2005 compared to 2004, the result of a higher proportion of distributor versus direct sales, partially offset by the favorable effect of a weaker U.S dollar relative to the Euro. Included in cost of product sales were royalty expenses of approximately $1.4 million and $1.3 million for the nine months ended September 30, 2005 and 2004, respectively.

Research and Development. The increase in research and development expense was primarily related to (i) approximately $2.2 million of increased costs related to our MIST UK study; (ii) increased legal fees of approximately $940,000 associated with patent infringement claims and ongoing patent research; (iii) approximately $700,000 of technology license and product development costs related to future generation implant technologies; (iv) approximately $600,000 of costs related to our BEST clinical study; and (v) increased headcount and related personnel costs of approximately $300,000. Combined costs of our CLOSURE I, MIST UK and BEST clinical studies totaled approximately $5.4 million for the nine months ended September 30, 2005 compared to approximately $2.6 million for the nine months ended September 30, 2004.

General and Administrative. The slight increase in general and administrative expense was primarily attributable to (i) increased stock-based compensation of approximately $276,000 related to our 2001 stock option re-pricing and (ii) increased professional fees, primarily related to corporate governance requirements of SOX, of approximately $150,000, partially offset by (i) reduced corporate legal fees of approximately $230,000 and (ii) reduced insurance costs of approximately $98,000.

Selling and Marketing. The increase in selling and marketing expense was the result of (i) an approximate $347,000 increase in sales incentive compensation; (ii) an approximate $114,000 increase in personnel and related costs; and (iii) an

15

approximate $56,000 increase in physician training and market research consulting services, partially offset by (i) the elimination of approximately $126,000 of 2004 costs related to our collaboration with the National Stroke Association; and (ii) an approximate $192,000 decrease in marketing program events.

Interest Income, Net. The increase in interest income was primarily attributable to higher weighted average interest rates earned due to (i) the increasing percentage of marketable securities versus cash equivalents in 2005 compared to 2004 and (ii) the general trend of increasing short-term interest rates. Average interest-bearing assets decreased by approximately $3.3 million, or 9.7%, during the nine months ended September 30, 2005 compared to 2004.

Income Tax Provision. We recorded no income tax provision for each of the nine-month periods ended September 30, 2005 and 2004 on the basis that our planned investments in MIST, MIST II, MIST III, CLOSURE I and BEST were expected to result in net operating losses for each of these fiscal years.

Income from Discontinued Operations. During the nine months ended September 30, 2005, we recorded approximately $91,000 of income from discontinued operations in connection with the final settlement of a tax claim related to our former neurosciences business unit (See Note 7 of Notes to Consolidated Financial Statements).

LIQUIDITY AND CAPITAL RESOURCES

	For The Nine Months Ended September 30,
	2005			2004
	(In thousands)
Cash, equivalents, marketable securities and restricted cash	$	33,419		$	35,464
Net cash used in operating activities		(2,335	)		(1,025	)
Net cash used in discontinued operations		(324	)		—
Net cash provided by (used in) investing activities		3,564			(14,959	)
Net cash provided by financing activities		1,187			515

Net Cash Used in Operating Activities:

Net cash used in operating activities for the nine months ended September 30, 2005 totaled approximately $2.3 million and consisted of a loss from continuing operations of approximately $5.2 million, offset by (i) net decreases in working capital requirements of approximately $2.0 million; and (ii) various non-cash charges to operations of approximately $925,000.

The non-cash charges of approximately $925,000 during the nine months ended September 30, 2005 consisted of (i) stock-based compensation, principally related to our 2001 stock option re-pricing, for which full vesting was completed in April 2005; (ii) amortization of bond premium related to our marketable securities investments; and (iii) depreciation of property and equipment.

The primary elements of the $2.0 million net decrease in working capital during the nine months ended September 30, 2005 consisted of the following:

(a) Net trade accounts receivable increased by approximately $537,000, primarily due to an increase of approximately $1.1 million in total product sales for the three months ended September 30, 2005 compared to the three months ended December 31, 2004, partially offset by a higher proportion of North American product sales, which generally have shorter collection cycles than European product sales.

(b) Our inventories decreased by approximately $633,000 during the nine months ended September 30, 2005, primarily due to planned reductions in production volumes.

(c) Prepaid expenses and other current assets decreased by approximately $29,000 during the nine months ended September 30, 2005. The decrease consisted primarily of (i) a $147,000 decrease in accrued interest receivable on interest-bearing investments; and (ii) an estimated $55,000 reduction in accrued royalties receivable from Bard and BSC, partially offset by (i) increases in other prepaid expense items of approximately $167,000; and (ii) an increase of $43,000 in prepaid insurance. The increase in other prepaid items consisted primarily of (i) $87,000 related to future marketing events; (ii) a $50,000 advance deposit for a capital equipment purchase; and (iii) $26,000 related to annual director and NASDAQ fees.

16

(d) Current liabilities increased by approximately $1.8 million, which primarily consisted of approximately (i) $360,000 of accrued expenses related to MIST; (ii) $300,000 of accrued expenses related to CLOSURE I; (iii) approximately $250,000 of legal and professional fees primarily in connection with ongoing patent infringement claims and SOX 404 compliance; (iv) $230,000 of accrued expenses related to BEST; (v) approximately $120,000 of sales commissions and royalties principally related to increased product sales; and (vi) $570,000 of accounts payable.

Net Cash Used in Discontinued Operations

On July 6, 2005, we settled a French tax claim related to our former neurosciences business unit, which was sold in 2002 to Integra. Pursuant to an indemnification agreement, we paid $324,267 to Integra.

Net Cash Provided By (Used) In Investing Activities

Net cash provided by investing activities of approximately $3.6 million during the nine months ended September 30, 2005 consisted primarily of (i) approximately $15.4 million of proceeds from maturities of marketable securities, offset by approximately $12.8 million of purchases of marketable securities; and (ii) an approximate $1.1 million release of restricted cash balances in connection with the settlement of the French tax claim, partially offset by purchases of property and equipment of approximately $135,000 for use in our manufacturing, research and development and general and administrative activities. This compared to net cash used in investing activities of approximately $15.0 million during the nine months ended September 30, 2004, which consisted primarily of (i) approximately $22.6 million of purchases of marketable securities, partially offset by $8.0 million of maturities of marketable securities; and (ii) purchases of property and equipment of approximately $335,000.

Net Cash Provided By Financing Activities

Net cash provided by financing activities was approximately $1.2 million and $515,000 for the nine months ended September 30, 2005 and 2004, respectively. For both periods, this was primarily attributable to proceeds from the exercise of common stock options and warrants and the issuance of common stock pursuant to our employee stock purchase plan.

Primarily as a result of the anticipated ongoing costs of the MIST, MIST II, MIST III, CLOSURE I and BEST clinical studies, we currently expect to incur operating losses at least through 2005 and into 2006. The total cost of our MIST study is currently estimated to be approximately $4.0 million through early 2006, at which time full data analysis is expected to be completed. Of this amount, approximately $900,000 was incurred in 2004 and we currently expect to incur approximately $2.9 million in 2005. The total cost of our CLOSURE I clinical trial is currently estimated to be approximately $24 million through completion of the trial and submission to the FDA. Of this amount, approximately $6.2 million was incurred through 2004 and we currently expect to incur approximately $3.5 million in 2005, largely dependent upon the rate of enrollment. The total cost of our BEST study is currently estimated to be approximately $1.5 - $2.0 million, of which approximately $1.4 - $1.6 million is anticipated to be incurred in 2005.

In September 2005, we received conditional FDA approval for an IDE to initiate enrollment in MIST II, our pivotal PFO/migraine clinical study. MIST II is a prospective, randomized, multi-center, controlled study designed to randomize approximately 600 migraine patients with a PFO to either PFO closure with our STARFlex^® technology or a control arm, and is expected to begin in early 2006, with patient follow-up over a one year period. We currently project the costs of this study to be in the range of $16 - $20 million through 2008, with 2005 costs currently estimated to be approximately $500,000.

In October 2005, we received approval in the United Kingdom to begin enrollment in MIST III. In MIST III, control patients from the original MIST study, those who did not receive the STARFlex^® implant, have the option to receive an implant after they have been unblinded as part of the MIST study. Patients who choose to receive an implant will be followed for six months. These patients will then be followed for an additional 18 months and will become their own control. In addition, migraine patients with a PFO who did receive a STARFlex^® implant in MIST will be followed for an additional 18 months. We currently estimate the costs of MIST III to be approximately $1.0 million.

In connection with the license and development agreement related to our BioSTAR™ product, we will be required to make an additional payment as of the first commercial sale of the BioSTAR™ product. Following the first commercial sale, we will be obligated to pay quarterly royalties on net commercial sales, as defined, subject to prescribed minimums in order to maintain our exclusive license rights.

Capital expenditures are currently estimated to total approximately $300,000 during 2005, primarily for manufacturing and research and development equipment.

17

We currently believe that the aggregate balance of cash, cash equivalents and marketable securities of approximately $33.4 million at September 30, 2005 will be sufficient to meet our working capital, financing and capital expenditure requirements through at least 2009. Based upon current projections, we expect that the aggregate balance of cash, cash equivalents, and marketable securities will approximate $29 - $30 million at the end of 2005.

OFF-BALANCE SHEET FINANCING

During the quarter ended September 30, 2005, we did not engage in material off-balance sheet activities, including the use of structured finance or specific purpose entities.

CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS

The following important factors, among others, could cause actual results to differ materially from those contained in forward-looking statements made in this Quarterly Report on Form 10-Q and presented elsewhere by us from time to time.

WE MAY FACE UNCERTAINTIES WITH RESPECT TO THE EXECUTION, COST AND ULTIMATE OUTCOME OF MIST.

In November 2004, we received approval to initiate our MIST clinical study in the United Kingdom. This study is designed to evaluate the effectiveness of transcatheter closure of a PFO in the treatment and prevention of migraine headaches. Patient enrollment was completed in early July 2005, with follow-up evaluations over a six-month period. We currently estimate the total costs of MIST, including third party contracts, agreements with clinical sites and other service providers, to be approximately $4.0 million. We cannot be certain that this prospective, randomized, controlled study will confirm clinical relevance between PFO and migraine headaches or that it will demonstrate the effectiveness of our proprietary technology in treating this condition. Even if we achieve positive results, we cannot be certain of the timing or the costs of obtaining required FDA approvals in order to market our STARFlex^® technology in the U.S. to treat migraines.

WE MAY FACE UNCERTAINTIES WITH RESPECT TO THE EXECUTION, COST AND ULTIMATE OUTCOME OF MIST II.

In September 2005, we received conditional approval from the FDA of an IDE to initiate enrollment in our pivotal PFO/migraine clinical study, named MIST II. MIST II is a prospective, randomized, multi-center, controlled study. The double-blinded trial is designed to randomize approximately 600 migraine patients with a PFO to either PFO closure with our STARFlex^® technology or a control arm. We currently expect patient enrollment to commence in early 2006, with patient follow-up over a one year period. We currently project the costs of this clinical study to be in the range of $16 - $20 million through 2008. We cannot be certain that this prospective, randomized, controlled study will confirm clinical relevance between PFO and migraine headaches or that it will demonstrate the effectiveness of our proprietary technology in treating this condition. We cannot be certain that our preliminary cost estimates for MIST II will not need to be adjusted upwards significantly. Furthermore, we cannot be certain that we will ultimately obtain a Pre-Market Approval (“PMA”) from the FDA based upon the final results of this study or whether further studies might be required by the FDA before consideration of a PMA. In addition, if patient enrollment were to progress as rapidly as we experienced for our MIST UK study, we cannot be certain of the effect, if any, on the level of commercial sales of our CardioSEAL^® products in the United States during the enrollment period.

CIRCUMSTANCES COULD CAUSE THE LOSS OF OUR HDE APPROVAL FOR USE OF CARDIOSEAL^® IN TREATING PFO PATIENTS.

All of our U.S. commercial sales of CardioSEAL^® are made pursuant to either: (a) the PMA granted by the FDA in December 2001 covering the ventricular septal defect (“VSD”) indication or (b) the HDE granted by the FDA in February 2000 covering the PFO indication. To the extent that we believe that PFO is the much larger market opportunity, a majority of our U.S sales are made under the PFO HDE. If the first PMA for the PFO indication were to be granted by the FDA to one of our competitors, our HDE approval for PFO would be deactivated by the FDA. Such a loss of our PFO HDE would cause a very material reduction in U.S. sales, resulting in significant operating losses based upon our current operational structure. Under these circumstances, and in the absence of substantial sources of new financing, our future prospects would be severely limited, including our ability to complete the CLOSURE I clinical trial that is required to apply for a PFO PMA.

WE MAY FACE UNCERTAINTIES WITH RESPECT TO THE EXECUTION, COST AND ULTIMATE OUTCOME OF CLOSURE I.

Upon receipt of final FDA approval, we commenced CLOSURE I in June 2003. During the two years ended September 30, 2005,

18

the rate of patient enrollment has been disappointing. We are continuing to work with our consultants, regulatory bodies and investigators to help complete enrollment by the end of 2006, but full enrollment may take longer. We currently estimate the total costs of CLOSURE I to be approximately $24 million through completion of the clinical trial and submission to the FDA. We have no direct experience conducting a clinical trial of this magnitude. We cannot be certain that patient enrollment will be completed within our revised time expectation or at all. We cannot be certain that the projected costs of CLOSURE I will not need to be adjusted upwards further. Furthermore, we cannot be certain that we will obtain a PMA from the FDA based upon the final results of the trial. If CLOSURE I does not result in a PMA, we may face uncertainties and/or limitations as to the continued growth of revenues of our CardioSEAL^® and STARFlex^® products, which may impact our profitability.

WE MAY FACE UNCERTAINTIES WITH RESPECT TO THE EXECUTION, COST AND ULTIMATE OUTCOME OF BEST.

In June 2005, we received approval to initiate our BEST clinical study in the United Kingdom. This study, designed to evaluate our new BioSTAR^™ PFO closure technology, is the first in-human use of a bioabsorbable collagen matrix incorporated on our STARFlex^® platform. We currently estimate total costs of this study, including third party contracts and agreements with clinical sites and other service providers, to be in the range of $1.5 – $2.0 million through early 2006. We cannot be certain that the projected costs of BEST will not need to be adjusted upwards. Furthermore, we cannot be certain that we will secure European commercial approval for our BioSTAR^™ technology through the CE Mark process.

SUBSTANTIALLY ALL OF OUR REVENUES ARE DERIVED FROM SALES OF ONE PRODUCT LINE.

We derive a substantial portion of our ongoing revenues from sales of our CardioSEAL^® and STARFlex^® products. In the United States, the FDA limits sales under an HDE to 4,000 units per year. As demand for, and costs associated with, these products fluctuates, including the potential impact of our non-revenue producing PFO IDE clinical trial on product sales, our financial results on a quarterly or annual basis may be significantly impacted. Accordingly, events or circumstances adversely affecting the sales of either of these products will directly and adversely impact our business. These events or circumstances may include reduced demand for our products, lack of regulatory approvals, product liability claims and/or increased competition.

WE MAY FACE UNCERTAINTIES WITH RESPECT TO COMMERCIALIZATION, PRODUCT DEVELOPMENT AND MARKET ACCEPTANCE OF OUR PRODUCTS.

We cannot be certain that our current products, or products currently under development, will achieve or maintain market acceptance. Certain of the medical indications that can be treated by our devices can also be treated by surgery, drugs or other medical devices. Currently, the medical community widely accepts many alternative treatments, and these other treatments have a long history of use. We cannot be certain that our devices and procedures will be able to replace such established treatments or that either physicians or the medical community, in general, will accept and utilize our devices or any other medical products that we may develop. In addition, our future success depends, in part, on our ability to develop additional products. Even if we determine that a product candidate has medical benefits, the cost of commercializing that product candidate may be too high to justify development. In addition, competitors may develop products that are more effective, cost less or are ready for commercial introduction before our products. If we are unable to develop additional, commercially viable products, our future prospects will be limited.

WE MAY FACE CHALLENGES IN EXECUTING OUR FOCUSED BUSINESS STRATEGY.

As a result of the 2001 sale of our vena cava filter product line and the 2002 sale of our neurosciences business unit, we have focused our business growth strategy to concentrate on the manufacturing, marketing and selling of our cardiac septal repair implant devices. Our future sales growth and financial results depend almost exclusively upon the growth of sales of this product line. CardioSEAL^® and STARFlex^® product sales may not grow as quickly as we expect for various reasons, including, but not limited to, delays in receiving further FDA approvals for additional indications and product enhancements, difficulties in recruiting additional experienced sales and marketing personnel and increased competition. This focus has placed significant demands on our senior management team and other resources. Our future success will depend on our ability to manage and implement our focused business strategy effectively, including by:

• achieving successful migraine and stroke-related clinical trials;

• developing next generation product lines;

• improving our sales and marketing capabilities;

• continuing to train, motivate and manage our employees; and

• developing and improving our operational, financial and other internal systems.

19

WE MAY BE UNABLE TO PROTECT OUR INTELLECTUAL PROPERTY RIGHTS AND MAY FACE INTELLECTUAL PROPERTY INFRINGEMENT CLAIMS.

Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of third parties. We cannot be certain that:

• any of our pending patent applications or any future patent applications will result in issued patents;

• the scope of our patent protection will exclude competitors or provide competitive advantages to us;

• any of our patents will be held valid if subsequently challenged; or

• others will not claim rights in or ownership of the patents and other proprietary rights held by us.

Furthermore, we cannot be certain that others have not or will not develop similar products, duplicate any of our products or design around any patents issued, or that may be issued, in the future to us or to our licensors. Whether or not patents are issued to us or to our licensors, others may hold or receive patents which contain claims having a scope that covers products developed by us. We could incur substantial costs in defending any patent infringement suits or in asserting any patent rights, including those granted by third parties. In addition, we may be required to obtain licenses to patents or proprietary rights from third parties. There can be no assurance that such licenses will be available on acceptable terms, if at all.

Our issued U.S. patents, and corresponding foreign patents, expire at various dates ranging from 2011 to 2019. When each of our patents expires, competitors may develop and sell products based on the same or similar technologies as those covered by the expired patent. We have invested in significant new patent applications, and we cannot be certain that any of these applications will result in an issued patent to enhance our intellectual property rights.

WE CANNOT BE CERTAIN THAT THE RECENT TREND OF NET ROYALTY INCOME WILL CONTINUE.

For the fiscal year ended December 31, 2004, net royalty income increased more than 200% compared to the fiscal year ended December 31, 2003. The year-over-year increase for the nine months ended September 2005 was 16.6%. As a percentage of our total revenues, net royalty income has increased from approximately 6.0% for fiscal year 2003 to approximately 19.5% for both the fiscal year ended December 31, 2004 and the nine months ended September 30, 2005. These increases have been directly attributable to higher sales by Bard of its RNF product, for which Bard received FDA approval for commercial sales and use as of December 31, 2002. We cannot be certain that the recent trend of Bard’s RNF sales can be sustained or even maintained at its current level. Furthermore, these sales levels could fluctuate on a quarter-to-quarter basis. We incur virtually no operating expenses related to our net royalty income and, therefore, future increases or decreases, if any, in the level of Bard’s RNF sales could have a material effect on net income (loss) in future periods. In addition, commencing in 2008, the royalty rate earned on Bard’s RNF sales will decrease substantially from its current rate.

OUR LIMITED MANUFACTURING HISTORY AND THE POSSIBILITY OF NON-COMPLIANCE WITH MANUFACTURING REGULATIONS RAISE UNCERTAINTIES WITH RESPECT TO OUR ABILITY TO COMMERCIALIZE FUTURE PRODUCTS.

We have a limited history in manufacturing our products, including our CardioSEAL^® and STARFlex^® cardiac septal repair implant devices, and we may face difficulties as the commercialization of our products and the medical device industry changes. Increases in our manufacturing costs, or significant delays in our manufacturing process, could have a material adverse effect on our business, financial condition and results of operations.

The FDA and other regulatory authorities require that our products be manufactured according to rigorous standards including, but not limited to, Good Manufacturing Practices and International Standards Organization (“ISO”) standards. These regulatory requirements may significantly increase our production or purchasing costs and may even prevent us from making or obtaining our products in amounts sufficient to meet market demand. If we or a third-party manufacturer change our approved manufacturing process, the FDA will require a new approval before that process could be used. Failure to develop our manufacturing capabilities may mean that even if we develop promising new products, we may not be able to produce them profitably, as a result of delays and additional capital investment costs.

WE MAY BE UNABLE TO SUCCESSFULLY GROW OUR PRODUCT REVENUES OR EXPAND GEOGRAPHICALLY DUE TO LIMITED MARKETING AND SALES EXPERIENCE.

Our cardiac septal repair implant devices are marketed primarily through our direct sales force. Since 2001, we have increased our combined U.S. and European sales and marketing organization headcount from 9 to 18. Due to our relatively

20

new sales staff, and because we have marketed our initial products (such as stents and vena cava filters) through third parties, we have limited experience marketing our products directly. We are uncertain that we can successfully expand geographically into Asia/Pacific or other potential markets for our products. In order to market directly the CardioSEAL^® and STARFlex^® septal implants and any related products, we will have to continue to develop a marketing and sales organization with technical expertise and distribution capabilities.

WE MAY BE UNABLE TO COMPETE SUCCESSFULLY BECAUSE OF INTENSE COMPETITION AND RAPID TECHNOLOGICAL CHANGE IN OUR INDUSTRY.

The medical device industry is characterized by rapidly evolving technology and intense competition. Existing and future products, therapies, technological approaches and delivery systems will continue to compete directly with our products. Many of our competitors have substantially greater capital resources, greater research and development, manufacturing and marketing resources and experience and greater name recognition than we do. In addition, new surgical procedures and medications could be developed that replace or reduce the importance of current or future procedures that utilize our products. As a result, any products that we develop may become obsolete before we recover any expenses incurred in connection with development of these products.

AN ADVERSE OUTCOME IN ANY LITIGATION WE ARE CURRENTLY INVOLVED IN COULD AFFECT OUR FINANCIAL CONDITION.

We are currently involved in the litigation of disputes as described in Item 1 of Part II (Legal Proceedings). An adverse outcome in any one of these disputes could result in substantial monetary damages and, therefore, negatively impact our financial condition or results of operations.

PRODUCT LIABILITY CLAIMS, PRODUCT RECALLS AND UNINSURED OR UNDERINSURED LIABILITIES COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS.

The testing, marketing and sale of implantable devices and materials carry an inherent risk that users will assert product liability claims against us or our third party distributors. In these claims, users might allege that their use of our devices had adverse effects on their health. A product liability claim or a product recall could have a material adverse effect on our business. Certain of our devices are designed to be used in life-threatening situations where there is a high risk of serious injury or death. Although we currently maintain limited product liability insurance coverage, we cannot be certain that in the future we will be able to maintain such coverage on acceptable terms, or that current insurance or insurance subsequently obtained will provide adequate coverage against any or all potential claims. Furthermore, we cannot be certain that we will avoid significant product liability claims and the attendant adverse publicity. Any product liability claim, or other claim, with respect to uninsured or underinsured liabilities could have a material adverse effect on our business.

INTENSE INDUSTRY COMPETITION FOR QUALIFIED EMPLOYEES COULD AFFECT OUR ABILITY TO ATTRACT AND RETAIN NECESSARY, QUALIFIED PERSONNEL.

In the medical device field, there is intense competition for qualified personnel and we cannot be assured that we will be able to continue to attract and retain the qualified personnel necessary for the development of our business. Both the loss of the services of existing personnel, as well as the failure to recruit additional qualified scientific, technical and managerial personnel in a timely manner, would be detrimental to our anticipated growth and expansion into areas and activities requiring additional expertise. The failure to attract and retain such personnel could adversely affect our business.

AS A RESULT OF GOVERNMENT REGULATIONS, WE MAY EXPERIENCE LOWER SALES AND EARNINGS.

The manufacture and sale of medical devices intended for commercial distribution are subject to extensive governmental regulations in the United States and abroad. Medical devices generally require pre-market clearance or pre-market approval prior to commercial distribution. Certain material changes or modifications to medical devices are also subject to regulatory review and clearance or approval. The regulatory approval process is expensive, uncertain and lengthy. If granted, the approval may include significant limitations on the indicated uses for which a product may be marketed. In addition, any products that we manufacture or distribute are subject to continuing regulation by the FDA. We cannot be certain that we will be able to obtain necessary regulatory approvals or clearances for our products on a timely basis or at all. The occurrence of any of the following events could have a material adverse effect on our business, financial condition and results of operations:

• delays in receipt of, or failure to receive, regulatory approvals or clearances;

• the loss of previously received approvals or clearances;

21

• limitations on the intended use of a device imposed as a condition of regulatory approvals or clearances; or

• our failure to comply with existing or future regulatory requirements.

In addition, sales of medical device products outside the United States are subject to foreign regulatory requirements that vary widely from country to country. Failure to comply with foreign regulatory requirements also could have a material adverse effect on our business, financial condition and results of operations.

WE FACE UNCERTAINTIES WITH RESPECT TO THE AVAILABILITY OF THIRD PARTY REIMBURSEMENT.

In the United States, Medicare, Medicaid and other government insurance programs, as well as private insurance reimbursement programs, greatly affect revenues for suppliers of health care products and services. Such third party payors may affect the pricing or relative attractiveness of our products by regulating the maximum amount, if any, of reimbursement which they provide to the physicians and hospitals using our devices, or any other products that we may develop. If, for any reason, the third party payors decided not to provide reimbursement for our products, our ability to sell our products would be materially adversely affected. Moreover, mounting concerns about rising health care costs may cause the government or private insurers to implement more restrictive coverage and reimbursement policies in the future. In the international market, reimbursement by private third party medical insurance providers and by governmental insurers and providers varies from country to country. In certain countries, our ability to achieve significant market penetration may depend upon the availability of third party governmental reimbursement.

WE MAY NEED TO RAISE DEBT OR EQUITY FUNDS IN THE FUTURE.

In the future, we may require additional funds for our research and product development programs, regulatory processes, preclinical and clinical testing, sales and marketing infrastructure and programs and potential licenses and acquisitions. Any additional equity financing may be dilutive to our stockholders, and additional debt financing, if available, may involve restrictive covenants. Our capital requirements will depend on numerous factors, including the level of sales of our products, the progress of our research and development programs, the progress of clinical testing, the time and cost involved in obtaining regulatory approvals, the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, competing technological and market developments, developments and changes in our existing research, licensing and other relationships and the terms of any collaborative, licensing and other similar arrangements that we may establish. We do not currently have any existing line of credit arrangements, and we may not be able to obtain any such credit facilities on acceptable terms, if at all.

WE WILL BE REQUIRED TO OBTAIN THE ATTESTATION OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM RELATING TO OUR INTERNAL CONTROLS OVER FINANCIAL REPORTING.

Section 404 of the Sarbanes-Oxley Act of 2002 requires that we receive the attestation of our independent auditors of the effectiveness of our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). As of June 30, 2005 we met the SEC definition of an accelerated filer. As a result, we must include in our fiscal 2005 Annual Report on Form 10-K, including our financial statements, our assessment of the effectiveness of our internal controls over financial reporting with our independent registered public accountant’s attestation. We have embarked on a program to review, document and test our internal controls over financial reporting for ultimate presentation to and review by our independent registered public accountants. While we believe our internal controls over financial reporting are adequate, there can be no assurances that we will receive the required attestation or that unforeseen circumstances will result in one or more of our controls becoming ineffective. If we are not able to implement the requirements of Section 404 in a timely manner, our future financial performance and the market price of our stock may be adversely affected, and we would potentially be subject to sanctions or investigations by regulatory authorities, including the SEC or The NASDAQ National Market.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of September 30, 2005 and December 31, 2004, we did not participate in any derivative financial instruments or other financial and commodity instruments for which fair value disclosure would be required under SFAS No. 107, “Disclosures About Fair Value of Financial Instruments”. Our investments are primarily short-term money market accounts that are carried on our books at cost, which approximates fair market value, and corporate and U.S. Government agency debt instruments that are carried on our books at amortized cost, increased or decreased by unrealized gains or losses, net of tax, respectively, which amounts are recorded as a component of stockholders’ equity in our consolidated financial statements. Accordingly, we have no quantitative information concerning the market risk of participating in such investments. We are subject to market risk in the form of foreign currency risk. We denominate certain product sales and operating expenses in

22

non-U.S. currencies, resulting in exposure to adverse movements in foreign currency exchange rates. These exposures may change over time and could have a material adverse impact on our financial condition.

We translate the accounts of our foreign subsidiaries in accordance with SFAS No. 52, “Foreign Currency Translation”. The functional currency of these foreign subsidiaries is the U.S. dollar and, accordingly, translation gains and losses are reflected in the consolidated statements of operations. Revenue and expense accounts are translated using the weighted average exchange rate in effect during the period.

ITEM 4. CONTROLS AND PROCEDURES

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2005. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2005, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended September 30, 2005 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In September 2004, we and CMCC filed a civil complaint in the U.S. District Court for the District of Minnesota for infringement of a patent owned by CMCC and licensed exclusively to us. The complaint alleges that Cardia of Burnsville, Minnesota is making, selling and/or offering to sell a medical device in the United States that infringes CMCC’s U.S. patent relating to a device and method for repairing septal defects. We sought an injunction from the court to prevent further infringement by Cardia, as well as monetary damages. The court has entered a pre-trial order stating that the case is to be ready for trial in the spring of 2006.

On March 22, 1999, we filed a patent infringement suit in the Court against AGA alleging that AGA was infringing United States Patent No. 5,108,420 (the “420 patent”), relating to aperture occlusion devices, to which we have an exclusive license. We sought an injunction from the Court to prevent further infringement by AGA, as well as monetary damages. On April 12, 1999, AGA served its answer and counterclaims denying liability and alleging that we had engaged in false or misleading advertising and in unfair or deceptive business practices. AGA’s counterclaims sought an injunction and an unspecified amount of damages. On May 3, 1999, we answered AGA’s counterclaims denying liability. On April 25, 2001, the Court granted our motion to stay all proceedings in this matter pending reexamination of the ‘420 patent by the United States Patent and Trademark Office and, on December 2, 2003, the Court dismissed our claim and AGA’s counterclaim without prejudice to our ability to refile suit after the conclusion of the reexamination proceedings. Although a Patent Office examiner initially rejected the claims of the ‘420 patent, on August 19, 2004, the Board of Patent Appeals and Interferences reversed the examiners rejection of the claims of the ‘420 patent and returned the reexamination for action consistent with its decision. On January 26, 2005, the Patent Office mailed a Notice of Intent to Issue a Reexamination Certificate. This reexamination certificate was issued on June 7, 2005. On October 13, 2004, AGA initiated a declaratory action in the United States District Court for the District of Minnesota seeking a declaration that the ‘420 patent is invalid, unenforceable, and not infringed. On December 7, 2004, we revived our original Massachusetts action by filing a complaint alleging that AGA is infringing the ‘420 patent. On September 1, 2005, AGA’s declaratory judgment action in the United States District Court for the District of Minnesota was transferred to the District of Massachusetts.

On or about September 24, 2001, each of the three French subsidiaries of our former neurosciences business unit received a Notification of Reassessment Following Verification of the Accounts (Notification de redressements suite à une vérification de comptabilité) from the French Direction de Controle Fiscal Sud-est (Nice) (“Reassessment”). The French authorities sought back taxes, interest and penalties in excess of FF 11 million, which was the currency in which the assessment was

23

made (approximately $2.0 million based upon the exchange rate at June 30, 2005). In connection with our sale of the neurosciences business unit to Integra in July 2002, we agreed to specifically indemnify Integra against any liability in connection with these tax claims. In order to continue to appeal the Reassessment, in October 2004 we provided the French authorities with a bank guarantee on behalf of Integra Neurosciences Implants SA totaling approximately 824,000 Euros (approximately $1.0 million based upon the exchange rate at June 30, 2005). On July 6, 2005, we settled the tax claim and, pursuant to the indemnification agreement, we paid $324,267 to Integra, which amount was net of a previous deposit payment of approximately $60,000. In connection with this settlement, we recorded income from discontinued operations of $90,687 in the second quarter of 2005.

Other than as described above, we have no material pending legal proceedings.

24

ITEM 6. EXHIBITS

Number	Description of Exhibit
31.1	Certification of John E. Ahern, President and Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification of Richard E. Davis, Vice President and Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certification of John E. Ahern, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Richard E. Davis, Vice President and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NMT MEDICAL, INC.
Date: November 2, 2005	By:	/s/                              JOHN E. AHERN
		John E. Ahern
		President and Chief Executive Officer
Date: November 2, 2005	By:	/s/                            RICHARD E. DAVIS
		Richard E. Davis
		Vice President and Chief Financial Officer

26

EXHIBIT INDEX

Number	Description of Exhibit
31.1	Certification of John E. Ahern, President and Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification of Richard E. Davis, Vice President and Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certification of John E. Ahern, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Richard E. Davis, Vice President and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.